Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
Date:5/21/2012

e treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the ongoing Phase 3 trials for Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by us and our Japanese partner; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our ongoing long-term Phase 3 clinical study the effects on iron storage parameters, intravenous (IV) iron and erythropoiesis-stimulating agent (ESA) use observed in previous clinical trials; the ability for Zerenex to generate cost savings for dialysis centers and payers; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this pres
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... announced the appointment of Joann V. Lofgren ... Market Development, effective July 6, 2015. In this role, ... executing on the company,s market and product development strategy ... to welcome Joann to the OncoSec team and have ...
(Date:7/5/2015)... TOKYO , July 6, 2015 ... first international symposium on Medical-Engineering Collaboration "Medicine ... on July 10, 2015 in Tokyo, ... or its medical applied research will present their ... technology and a new industry produced with 8K ...
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... MATEO, Calif., Feb. 28, 2011 Nile Therapeutics, Inc. ... the development of novel therapeutics for heart failure patients, ... MDT ) on the clinical development of ... failure and renal disease applications. "We are ...
... 2011 Hotspur Technologies announced today that Dr. ... clinical use of its Keeper™ Embolectomy Catheter.  The ... within arteries, while also incorporating the capability of ... The Keeper Catheter combines a compliant ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2
(Date:7/6/2015)... , ... July 06, 2015 , ... University of ... national guidelines for thyroid cancer testing to reflect newly available tests that better incorporate ... use and how to interpret thyroid cancer tests is published in the July issue ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... from nurses or midwives, yet there is a large gap between the unmet ... research required to improve health outcomes and reduce unnecessary or ineffective treatments or ...
(Date:7/6/2015)... ... July 06, 2015 , ... doTERRA, the leading global essential oils company, ... Most recently, Jowers held the position as Director of the Hinckley Institute at the ... decade building the institute, Jowers states that he was ready for a new challenge, ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a new community program ... up with Family Emergency Shelter Coalition (FESCO) and announced a new charity campaign ... especially to provide emergency services and support for homeless families, all the while ...
(Date:7/6/2015)... ... ... World renowned Los Angeles facial plastic surgeon , Dr. Paul Nassif, ... solutions. Individuals that want to make multiple changes to their facial appearance are able ... of their needs. , "Anytime I see an opportunity to change the life ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... Pediatric rankings include top 30 hospitals in six specialty fields ... ... 30 U.S.News & World Report, one of the,nation,s leading sources of ... Children,s Hospitals,published online at http://www.usnews.com/pediatrics and in the magazine,s,June 9 ...
... Company to evaluate appeal options, TORONTO, May ... PMD; Amex: PME) today announced it has been ... it will not continue to,support PreMD,s plan for ... it intends to delist the Company,s common stock ...
... cancer were more likely than whites to die in ... among blacks for life-extending treatment even in the face ... by researchers at Dana-Farber Cancer Institute in Boston. ,The ... meeting of the American Society of Clinical Oncology in ...
... finds , , FRIDAY, May 30 (HealthDay News) -- Cirque ... to those of elite athletes in competitive sports, say ... 2006. , Injuries of the knee and ankle were ... all injuries to the upper extremities. Most injuries (45 ...
... GLENWOOD, Ill., May 30 Landauer, Inc. (NYSE:,LDR) announced ... cash dividend of $0.50 per share for the third ... July 3, 2008, to shareholders of record,on June 13, ... provider of analytical services to determine,occupational and environmental radiation ...
... One of the Easiest Paths to Fitness, INDIANAPOLIS, May ... fitness method, think again: taking a stroll is,an easy way ... according to three researchers who presented findings today at the,55th ... A study of 14 morbidly obese patients was designed to ...
Cached Medicine News:Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 2Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Black patients with terminal cancer more likely to choose aggressive care at end of life 2Health News:Injury Patterns Similar for 'Circus' Artists, Elite Athletes 2Health News:Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese 2
Round solid 15 mm wide lower plate. Open upper plate with inside diameter 12 mm. Serrated handle with locking thumb screw and polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
The popular E2002 Utrata Capsulorhexis Forceps with fine angled sharp tips. Angled 12 mm shafts with an iris stop. Flat handle with dull finish....
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Medicine Products: